Dr. Buzz Hollander, a family physician in Hawaii, joins Mark Reardon to discuss Pfizer's maternal RSV vaccine falling short, but it probably won't stop it from, being approved.
“It might sound like, ‘Oh, one more vaccine, what’s all the excitement?’ RSV is a big deal and I think people understand that more because we hear about it a lot,” shared Dr. Hollander
He continued, “RSV is a big deal because it puts infants, as well as small children, in the hospital at a higher rate than any other respiratory virus.”
“Creating a vaccine for RSV has been like a vaccinologist’s Moby Dick because it puts 1-2% of U.S. infants in the hospital every year. That’s a big number for our most vulnerable and the one group everybody is trying to protect more than any other,” concluded Dr. Hollander.
